ASX Share rice
Sun 16 May 2021 - 05:43:am (Sydney)

RNO Share Price

RHINOMED LIMITEDRNOPharmaceuticals, Biotechnology & Life Sciences

RNO Company Information

Name:

Rhinomed Limited

Sector:

Healthcare

Industry:

Medical Devices

GIC Industry:

Pharmaceuticals

GIC Sub Industry:

Pharmaceuticals

Address:

132 Gwynne Street Richmond VIC Australia 3121

Phone:

61 3 8416 0900

CEO, MD & Exec. Director:

Mr. Michael Johnson

CFO & Company Sec.:

Mr. Sean Slattery

Company Overview:

Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. It identifies, acquires, and commercializes nasal stent delivery technologies. The company's product portfolio includes Turbine for enhanced breathing in sports; Mute, an anti-snoring device; and Pronto for nasal congestion and sleep disturbance issues. It also engages in developing applications for the delivery of medical cannabis and conditions, including anxiety, pain, allergies, nausea, anxiety, and coughs and colds; and nasal swab to test the presence of upper respiratory tract diseases, including influenza, and coronavirus strains. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is based in Richmond, Australia.

RNO Share Price Information

Shares Issued:

253.81M

Market Capitalisation:

$40.61M

Revenue (TTM):

$4.58M

Revenue Per Share (TTM):

$0.02

Earnings per Share:

$-0.045

Profit Margin:

-1.629

Operating Margin (TTM):

$-1.71

Return On Assets (TTM):

$-0.53

Return On Equity (TTM):

$-1.04

Quarterly Revenue Growth (YOY):

0.198

Gross Profit(TTM):

$2.79M

Diluted Earnings Per Share (TTM):

$-0.035

RNO CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$6.32K

Change To Liabilities:

$-56,271

Total Cashflow From Investing Activities:

$-4,706

Net Income:

$-7,266,223

Total Cash From Operating Activities:

$-5,740,261

Depreciation:

$565.29K

Other Cashflow From Investing Activities:

$6.32K

Change To Inventory:

$-203,412

Change To Account Receivables:

$-304,733

Sale Purchase Of Stock:

$12.51M

Capital Expenditures:

$11.02K

RNO Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-7,265,430

Net Income:

$-7,266,220

Gross Profit:

$2.13M

Operating Income:

$-7,937,290

Other Operating Expenses:

$812.63K

Income Tax Expense:

$789

Total Revenue:

$3.58M

Cost Of Revenue:

$1.45M

RNO Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$1.03M

Total Liabilities:

$1.96M

Total Stockholder Equity:

$10.86M

Other Current Liabilities:

$822.56K

Total Assets:

$12.81M

Common Stock:

$71.27M

Other Current Assets:

$245.48K

Retained Earnings:

$-62,799,630

Other Liabilities:

$77.98K

Good Will:

$1.57M

Other Assets:

$161.93K

Cash:

$7.76M

Total Current Liabilities:

$1.41M

Property - Plant & Equipment:

$650.61K

Net Tangible Assets:

$8.43M

Long-Term Investments:

$80.85K

Total Current Assets:

$9.49M

Net Receivables:

$0.94M

Short-Term Investments:

$3.32M

Inventory:

$540.38K

Accounts Payable:

$314.91K

Short-Term Investments:

$3.32

Non Current Liabilities Total:

$548.45K

RNO Share Price History

RNO News

18 Feb, 2021
Michael Johnson is the CEO of Rhinomed Limited ( ASX:RNO ), and in this article, we analyze the executive's...
20 Dec, 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
07 Dec, 2020
Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the Innovation Virtual lnvestor Conference are now available for on-demand viewing.
02 Dec, 2020
Rhinomed Ltd (OTCQB:RHNMF), based in Australia, focused on Nasal Airway Technology today announced that Michael Johnson, CEO will present live at VirtualInvestorConferences.com on December 3rd.
30 Nov, 2020
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Innovation lnvestor Conference. Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 8:45 AM ET on Thursday, December 3rd with the first live webcast at 9:00 AM ET.
05 Oct, 2020
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Growth Opportunities Virtual lnvestor Conference. Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 9:00 AM ET on Thursday, October 8th with the first live webcast at 9:15 AM ET
21 Sep, 2020
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...